Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Multiple Myeloma
Conditions
Relapsed/Refractory Multiple Myeloma
Trial Timeline
Jul 11, 2016 โ Aug 15, 2022
NCT ID
NCT02755597About Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax is a phase 3 stage product being developed by AbbVie for Relapsed/Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT02755597. Target conditions include Relapsed/Refractory Multiple Myeloma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02755597 | Phase 3 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Multiple Myeloma